Filtered By:
Source: Neurology
Condition: Bleeding

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 78 results found since Jan 2013.

Why Ischemic Stroke Patients Do Not Receive Thrombolytic Treatment? (P7.122)
CONCLUSIONS:This retrospective analysis suggests that less than half of the patients presenting within 4 hours of symptom onset receive rt-PA. The most common reason was minor or rapidly improving symptoms. A significant proportion of patients did not receive rt-PA because patient or family refused. Minority of patients had absolute contraindication. More patient and family education is needed to allay fears of rt-PA use.Disclosure: Dr. Lee has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lahoti, S., Lee, J. Tags: Cerebrovascular Disease and Interventional Neurology: Issues in Acute Stroke Treatment Source Type: research

Risk of Bleeding from Antithrombotic Agents (AT) in Patients with Cerebral Cavernous Malformations (CCMs). (I2-1.002)
CONCLUSIONS: There is no apparent increase in the rate of hemorrhage in CCM patients while taking AT, although the small number of patients may limit the power to detect a difference. We are expanding this study to include a larger clinical database.Study Supported by:Disclosure: Dr. Wityk has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Wityk, R. Tags: New Antithrombotic Agents for Stroke Prevention Poster Presentations Source Type: research

Oral Anticoagulant Therapy Is Associated with Cerebral Microbleeds (I2-2.001)
Conclusions: OAT relates to both prevalent and incident microbleeds. Furthermore, maximum INR values and variability in INR are risk factors for microbleeds, particularly deep or infratentorial microbleeds.Study Supported by: Erasmus Medical Center;Research Institute for Diseases in the Elderly;Ministry of Education, Health,Welfare and Sports.Disclosure: Dr. Akoudad has nothing to disclose. Dr. Darweesh has nothing to disclose. Dr. Leening has nothing to disclose. Dr. Koudstaal has nothing to disclose. Dr. Hofman has received personal compensation in an editorial capacity for the European Journal of Epidemiology. Dr. Van D...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Akoudad, S., Darweesh, S., Leening, M., Koudstaal, P., Hofman, A., Van Der Lugt, A., Stricker, B., Ikram, M., Vernooij, M. Tags: New Antithrombotic Agents for Stroke Prevention Data Blitz Presentations Source Type: research

Direct Thrombin Inhibitors May Have A Decreased Risk Of Intracerebral Hemorrhage Compared With Older Anticoagulants (P5.140)
CONCLUSIONS: We found no significant difference in risk of ICH with DTI compared to the AC group and a trend towards lower risk with DTI. Future studies with larger numbers on DTIs are needed to confirm differences in ICH risk between DTIs and other anticoagulants.Disclosure: Dr. Ravipati has nothing to disclose. Dr. Woo has received research support from the National Institutes of Health. Dr. Sekar has received research support from the National Institutes of Health. Dr. Moomaw has received research support from the National Institutes of Health. Dr. Flaherty has received personal compensation for activities with CSL Behr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ravipati, S., Woo, D., Sekar, P., Moomaw, C., Flaherty, M., Osborne, J. Tags: Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage and Other Hemorrhages Source Type: research

Use of Apixaban and Warfarin in Patients Undergoing Procedures: Insights from ARISTOTLE (I2-2.003)
CONCLUSIONS: Procedures are common in patients with atrial fibrillation. The majority of procedures are non-major and non-emergent, and anticoagulation therapy is likely to be stopped peri-procedure. Overall and among emergent procedures, rates of clinical events in the first 30 days post-procedure were low and comparable between treatment groups.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance (i.e., formatting the abstract to ensure compliance with AAN guidelines) was provided by Claire Hall of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Lopes, R., Garcia, D., Wojdyla, D., Dorian, P., Alexander, J., Wallentin, L., Lanas, F., Hanna, M., Held, C., Granger, C. Tags: New Antithrombotic Agents for Stroke Prevention Data Blitz Presentations Source Type: research

Direct Thrombin Inhibitors May Have A Decreased Risk Of Intracerebral Hemorrhage Compared With Older Anticoagulants (I2-2.005)
CONCLUSIONS: We found no significant difference in risk of ICH with DTI compared to the AC group and a trend towards lower risk with DTI. Future studies with larger numbers on DTIs are needed to confirm differences in ICH risk between DTIs and other anticoagulants.Disclosure: Dr. Ravipati has nothing to disclose. Dr. Woo has received research support from the National Institutes of Health. Dr. Sekar has received research support from the National Institutes of Health. Dr. Moomaw has received research support from the National Institutes of Health. Dr. Flaherty has received personal compensation for activities with CSL Behr...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Ravipati, S., Woo, D., Sekar, P., Moomaw, C., Flaherty, M., Osborne, J. Tags: New Antithrombotic Agents for Stroke Prevention Data Blitz Presentations Source Type: research

Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Objective: To update the 1998 American Academy of Neurology practice parameter on stroke prevention in nonvalvular atrial fibrillation (NVAF). How often do various technologies identify previously undetected NVAF? Which therapies reduce ischemic stroke risk with the least risk of hemorrhage, including intracranial hemorrhage? The complete guideline on which this summary is based is available as an online data supplement to this article. Methods: Systematic literature review; modified Delphi process recommendation formulation. Major conclusions: In patients with recent cryptogenic stroke, cardiac rhythm monitoring probabl...
Source: Neurology - February 24, 2014 Category: Neurology Authors: Culebras, A., Messe, S. R., Chaturvedi, S., Kase, C. S., Gronseth, G. Tags: All Cerebrovascular disease/Stroke SPECIAL ARTICLE Source Type: research

ASA failure: Does the combination ASA/clopidogrel confer better long-term vascular protection?
Conclusions: In patients with a recent lacunar stroke while taking ASA, the addition of clopidogrel did not result in reduction of vascular events vs continuing ASA only. Classification of evidence: This study provides Class I evidence that for patients with recent lacunar stroke while taking ASA, adding clopidogrel as compared to continuing ASA alone does not reduce the risk of recurrent stroke.
Source: Neurology - February 3, 2014 Category: Neurology Authors: Cote, R., Zhang, Y., Hart, R. G., McClure, L. A., Anderson, D. C., Talbert, R. L., Benavente, O. R. Tags: Stroke prevention, Infarction ARTICLE Source Type: research

Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy
Conclusions: Our findings indicate that cSS, particularly if disseminated, is associated with an increased risk of symptomatic lobar ICH in CAA. cSS may help stratify future bleeding risk in CAA, with implications for prognosis and treatment.
Source: Neurology - November 4, 2013 Category: Neurology Authors: Charidimou, A., Peeters, A. P., Jager, R., Fox, Z., Vandermeeren, Y., Laloux, P., Baron, J.-C., Werring, D. J. Tags: MRI, All Cerebrovascular disease/Stroke, Intracerebral hemorrhage ARTICLE Source Type: research

Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Objective: To assess evidence regarding periprocedural management of antithrombotic drugs in patients with ischemic cerebrovascular disease. The complete guideline on which this summary is based is available as an online data supplement to this article. Methods: Systematic literature review with practice recommendations. Results and recommendations: Clinicians managing antithrombotic medications periprocedurally must weigh bleeding risks from drug continuation against thromboembolic risks from discontinuation. Stroke patients undergoing dental procedures should routinely continue aspirin (Level A). Stroke patients underg...
Source: Neurology - May 27, 2013 Category: Neurology Authors: Armstrong, M. J., Gronseth, G., Anderson, D. C., Biller, J., Cucchiara, B., Dafer, R., Goldstein, L. B., Schneck, M., Messe, S. R. Tags: Ultrasound, All Medical/Systemic disease, All Neuro-ophthalmology, All Cerebrovascular disease/Stroke, All Trauma SPECIAL ARTICLE Source Type: research

Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis
Conclusion: This study lends strong support to the concept that prominent fibrinogen turnover after IV stroke thrombolysis—a condition termed "early fibrinogen degradation coagulopathy"—is a relevant cause of major bleeding complications. Rigorous testing of more fibrin-specific thrombolytic agents in the setting of acute stroke is warranted.
Source: Neurology - March 25, 2013 Category: Neurology Authors: Matosevic, B., Knoflach, M., Werner, P., Pechlaner, R., Zangerle, A., Ruecker, M., Kirchmayr, M., Willeit, J., Kiechl, S. Tags: Other cerebrovascular disease/ Stroke, Clinical trials Observational study (Cohort, Case control) ARTICLE Source Type: research

Ischemic Stroke Related to Severe Iron-Deficiency Anemia in Adults May Benefit from Blood Transfusion (P01.232)
CONCLUSIONS: Prevalence of IDA is 1-20%; it is 3.9% in our AIS population and is often related to untreated uterine bleeding. As described in the pediatric population, severe IDA may be an underlying mechanism of ischemic stroke in adults, therefore, efforts must be undertaken to identify and treat the cause of the anemia. While patients with AIS and severe IDA may receive TPA, blood transfusion may be considered as an adjuvant therapy.Supported by: SPOTRIAS P50 NS044227 & NIH Training Grant 5T 32NS0077412-12.Disclosure: Dr. Choi has nothing to disclose. Dr. Sanchez-Rotunno has nothing to disclose. Dr. Gonzales has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Choi, E., Sanchez-Rotunno, M., Gonzales, N. Tags: P01 Cerebrovascular Disease I Source Type: research

An Analog of gamma-Glutamyl-Cysteine Is a More Stable Drug for the Potential Treatment of Stroke (P01.248)
CONCLUSIONS: The data suggest that the D-analog of Gamma-Glu-Cys may serve as a more stable therapeutic agent.Disclosure: Dr. Forman has nothing to disclose. Dr. Ikpa has nothing to disclose. Dr. Garchow has nothing to disclose. Dr. Sukowski has nothing to disclose. Dr. Peterson has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Forman, R., Ikpa, N., Garchow, K., Sukowski, E., Peterson, D. Tags: P01 Cerebrovascular Disease I Source Type: research

Fatal Embolic Stroke Due to Non-Atherothrombotic Mobile Thrombi in the Carotid Artery during Gastric Cancer Chemotherapy: An Autopsy Case Report (P01.255)
CONCLUSIONS: Multiple etiologies for ischemic stroke may exist in cancer patients. A mobile thrombus in the carotid artery should be considered as a possible mechanism for arteriogenic stroke in the clinical settings of malignancy with hypercoagulability. Doppler ultrasonography is the most practical tool to identify these conditions.Disclosure: Dr. Yamada has nothing to disclose. Dr. Yoneda has nothing to disclose. Dr. Arakawa has nothing to disclose. Dr. Adachi has nothing to disclose. Dr. Gotoh has nothing to disclose. Dr. Takagi has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Yamada, A., Yoneda, J., Arakawa, C., Adachi, T., Gotoh, J., Takagi, M. Tags: P01 Cerebrovascular Disease I Source Type: research

"Fou Rire Prodromique" as the Presentation of a Left Frontal Ischemic Stroke (P02.040)
CONCLUSIONS: Frontal lobe involvement affecting the Broca's area, as we described in our case, has only been described once. We conclude that the patient's laughter attack was the initial manifestation of the stroke suggesting that an acute infarct of Broca's area is capable of producing this unusual clinical presentation.Disclosure: Dr. Rosales has nothing to disclose. Dr. Garcia-Gracia has nothing to disclose. Dr. Salgado has received personal compensation in an editorial capacity from Belvoir Media Group as Consulting Editor of A Special Report published by the editors of Heart Advisor Cleveland Clinic STROKE: Advances ...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Rosales, D., Garcia-Gracia, C., Salgado, E. Tags: P02 Cerebrovascular Disease II Source Type: research